- Appointment to senior leadership team strengthens the Company’s plans for continued growth to advance its commercial ambitions
Cambridge, UK, 13 December, 2023: Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, is pleased to announce the appointment of Dr. Graeme Daniels, PhD, as the new Vice President of Sales and Marketing. In his role within the senior leadership team, Graeme will lead the international sales and marketing strategy, building on the rapid growth and market presence gained from the Company’s rebrand and extensive state-of-the-art facility expansion earlier this year1,2.
With over 20 years of experience in the life sciences and biotechnology industries, Graeme brings broad knowledge and past success to Sphere Fluidics. His strategic vision and leadership skills will play a pivotal role in advancing the Company’s mission to empower researchers and scientists with cutting-edge technologies for single-cell analysis.
Graeme joins from Revvity, Inc., a global life science and diagnostics company, where he was Global Sales Leader of Pharma Services, successfully developing and implementing sales strategies internationally. His expertise in building high-performing teams and cultivating strong customer relationships will support Sphere Fluidics in its commitment to delivering exceptional value to its customers. Graeme holds a PhD in Developmental Biology from the University of Edinburgh and a BSc in Molecular Genetics in Biotechnology from the University of Sussex.
“We’re very excited to welcome Graeme to the Sphere Fluidics’ team. His extensive experience and leadership in the life sciences industry will be instrumental in driving our international sales and marketing initiatives,” said Dr. Frank Craig, CEO, Sphere Fluidics. “As we continue to innovate and expand our product portfolio, his strategic insights will be invaluable in positioning Sphere Fluidics as a leader in single-cell analysis technologies.”
Dr. Graeme Daniels, Vice President of Sales and Marketing, Sphere Fluidics, commented: “Sphere Fluidics is well known across the industry for its commitment to advancing scientific research through groundbreaking technologies. I am honored and excited to take this exciting next step in my career, and look forward to working with this highly talented team to accelerate growth and further establish the Company as a key player in the life sciences industry.”
- Press release (23rd May, 2023): Sphere Fluidics updates brand identity to align with ambitious, global commercial growth strategy https://spherefluidics.com/sphere-fluidics-updates-brand-identity-to-align-with-ambitious-global-commercial-growth-strategy/
- https://www.news-medical.net/news/20231025/Sphere-Fluidics-Expansion-and-Vision.aspx
For further information please contact:
Colette Cooley
Sphere Fluidics Ltd.
Tel: +44 (0) 1223 942059
Email: colette.cooley@spherefluidics.com
Zyme Communications
Lily Jeffery
Tel: +44 (0)7891 477 378
Email: lily.jeffery@zymecommunications.com
About Sphere Fluidics:
Sphere Fluidics develops and manufactures single cell analysis and monoclonality assurance systems to enable researchers to find, analyze and isolate the most valuable cells, with ease and speed.
Sphere Fluidics’ proprietary picodroplet microfluidic platforms are designed specifically for single-cell screening and isolation, allowing users to encapsulate and analyze single cells within a picodroplet, while maintaining viability. Harnessing this technology, the Company’s range of novel microfluidic tools facilitate leading-edge research and accelerate biotherapeutic discovery and development, cell therapy, and synthetic biology workflows, streamlining the journey of discovery in labs, globally.
Sphere Fluidics is based at Granta Park in Cambridgeshire (UK). The Company has also internationalized its business via a global network of distributors.
